ACR Convergence 2025

October 24-29, 2025. Chicago, Illinois.

View by Number View by Title View Sessions

Abstract Number: 0253

Ophthalmology Screening for Asymptomatic Uveitis in Sarcoidosis Patients: A Single-Center Investigation
Abstract Number: 0254

Comparative Outcomes in MAGIC Syndrome versus Relapsing Polychondritis Alone: A Propensity-Matched Analysis
Abstract Number: 0255

Clearing the Smoke: Association Between Cannabis Use and Autoimmune Disease Incidence in a Retrospective Cohort Analysis
Abstract Number: 0256

The Role of Extracorporeal Membrane Oxygenation in Cardiopulmonary Dysfunction Due to Rheumatologic Diseases: A Systematic Review
Abstract Number: 0257

Safety of Guselkumab in Inflammatory Bowel Disease Up to 1 Year: Integrated Safety Analysis of Phase 2 and 3 Studies in Crohn’s Disease and Ulcerative Colitis
Abstract Number: 0258

Performance characteristics of anti-Collagen II antibodies for diagnosing inflammatory and non-inflammatory diseases: a systematic review and meta-analysis
Abstract Number: 0259

Inhaled pirfenidone as an innovative therapeutic approach to treat autoimmune ILD and other forms of Progressive Pulmonary Fibrosis: Phase 2b Study Design
Abstract Number: 0260

Development of a Consensus Definition of VEXAS Flare for Use in Clinical Research
Abstract Number: 0261

Randomized Confirmatory Basket Trial: Performance Evaluation of a Simulated Application Example in Rare Disease Using Real World Data
Abstract Number: 0262

Preclinical Characterization of ABB071 – a Humanized anti-CD180 Antibody that Modulates Multiple Pro-inflammatory Immune Pathways for the Treatment of Autoimmune and Inflammatory Disorders
Abstract Number: 0263

A Multicenter Retrospective Case Series of Patients with Susac Syndrome treated with Rituximab
Abstract Number: 0264

Seeing Beyond the Eye: Subclinical Audio-Vestibular Involvement in Vogt-Koyanagi-Harada Disease
Abstract Number: 0265

Influence of Menopausal Status on Coronary Artery Calcium Burden and Cardiovascular Computed Tomography Abnormalities in Inflammatory Arthritis
Abstract Number: 0266

Chronic PPI Use Association with Development of Autoimmune Conditions: Retrospective Cohort Study
Abstract Number: 0267

Pharmacosurvellience study of FDA Adverse Event Reporting System (FAERS) events of Secukinumab and Guselkumab

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].